CL V2 Pediatrics - Allergy Medications

Food Insecurity and the Dangers of Infant Formula Dilution

Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.

January 30th 2023

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024

Demystifying Infant Formula

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

October 11th 2022

Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.

Incorporating objective testing to add value to an ADHD diagnosis

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Related Content

April 25th 2024

Food Insecurity and the Dangers of Infant Formula Dilution

Perry Roy, MD, explains how an FDA-cleared objective test can assist in an ADHD diagnosis.

January 30th 2023

FDA approves tovorafenib for most common form of childhood brain tumor

April 24th 2024

Demystifying Infant Formula

This decision from the federal agency marks the first FDA approval of a systemic therapy to treat patients with pediatric LGG with BRAF rearrangements, including fusions.

October 11th 2022

Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.